The right diagnosis,
right away,
at the right price.

We are the creators of Genomtec ID, a mobile platform for genetic diagnostics at the point of patient care. We have just obtained our CE-IVD Mark for the GenomtecID Respiratory Panel 5-Plex (RP5-PLEX) which detects viruses and bacteria causing respiratory tract infections, the only solution of this kind in Europe. See more >>



Polish Financial Supervision Authority approved the Genomtec S.A. prospectus

In the next few days, the company expects to apply to the Warsaw Stock Exchange for admission and listing of Genomtec S.A. shares on the Warsaw Stock Exchange.


Value of the intellectual property portfolio of Genomtec S.A. estimated at EUR 191.336 million

Genomtec S.A. received from the German company Dennemeyer Consulting GmbH a valuation of the Company’s intellectual property portfolio. According to the DIN/ISO 77100 standard adopted by Dennemeyer, covering 9 patents held by Genomtec and 26 patent applications, as well as the conversion of all patent applications into patents, as well as a 14-year protection period […]


Genomtec S.A. signs an agreement with transaction advisor Clairfield Partners LLC

Genomtec S.A., a medical technology company specializing in the development of advanced technologies in the field of genetic diagnostics, has signed an agreement with Clairfield Partners LLC, the New York based member firm of Clairfield International (“Clairfield”). The purpose of the agreement is to advise on the process of establishing strategic partnerships, selling licenses and/or […]